Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Factors predictive for response of follicular and mantle-cell lymphoma to rituximab

Nature Clinical Practice Oncology volume 3, pages 184–185 (2006)Cite this article

boxed-textGhielmini M et al. (2005) Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16: 1675–1682

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ghielmini M et al. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23: 705–711

    Article  CAS  Google Scholar 

  2. Ghielmini M et al. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103: 4416–4423

    Article  CAS  Google Scholar 

  3. Hiddemann W et al. (2005) Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 23: 6394–6399

    Article  CAS  Google Scholar 

  4. Fisher RI et al. (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23: 8447–8452

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Michael Pfreundschuh, Professor of Internal Medicine at Saarland University Medical School, Homburg, Germany.

Author information

Authors and Affiliations

  1. Professor of Internal Medicine at Saarland University Medical School, Homburg, Germany

    Michael Pfreundschuh

Authors
  1. Michael Pfreundschuh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Pfreundschuh.

Ethics declarations

Competing interests

Dr Pfreundschuh is a member of the advisory board for Mabthera (Roche).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfreundschuh, M. Factors predictive for response of follicular and mantle-cell lymphoma to rituximab. Nat Rev Clin Oncol 3, 184–185 (2006). https://doi.org/10.1038/ncponc0457

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0457

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing